All In Biotech

Drug Trial Radar · NCT05673811

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Jan 10, 2023

Primary completion

Mar 28, 2025

Study completion Mar 28, 2025

Sponsor

Lead sponsor
Theriva Biologics SLIndustry
Sponsor type
Industry
First posted
Jan 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Conditions

  • Pancreatic Adenocarcinoma
  • Metastatic

Interventions

  • Nab-paclitaxelDrug

    Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

  • GemcitabineDrug

    Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

  • VCN-01Genetic

    VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From date of randomization until the date of death from any cause, assessed up to 27 months
  2. Number of TEAEs in Each Treatment ArmTime frame: until the end of treatment period phase

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • University of California - Davis Cancer Center

    Sacramento, California

  • University of Louisville - Brown Cancer Center

    Louisville, Kentucky

  • Weill Cornell Medical Center

    New York, New York

  • Martha Morehouse Tower

    Columbus, Ohio

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital Duran i Reynals (ICO)

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Gregorio Marañon

    Madrid, Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga, Spain

  • Hospital General Univesitario de Valencia

    Valencia, Valencia, Spain

  • Hospital Miguel Servet

    Zaragoza, Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.